Literature DB >> 14209796

FROM CYTASES TO LYSOSOMES.

C DEDUVE.   

Abstract

Keywords:  CYTOLOGY; ENZYMES; EXPERIMENTAL LAB STUDY; HYDROGEN-ION CONCENTRATION; HYDROLASES; LYSOSOMES; METABOLISM; NOMENCLATURE; PINOCYTOSIS

Mesh:

Substances:

Year:  1964        PMID: 14209796

Source DB:  PubMed          Journal:  Fed Proc        ISSN: 0014-9446


× No keyword cloud information.
  54 in total

1.  Neuronal lysosomal enzyme replacement using fragment C of tetanus toxin.

Authors:  K Dobrenis; A Joseph; M C Rattazzi
Journal:  Proc Natl Acad Sci U S A       Date:  1992-03-15       Impact factor: 11.205

2.  Alglucerase for Gaucher's disease: dose, costs and benefits.

Authors:  E Beutler; A M Garber
Journal:  Pharmacoeconomics       Date:  1994-06       Impact factor: 4.981

Review 3.  The role of glucocerebrosidase mutations in Parkinson disease and Lewy body disorders.

Authors:  Arash Velayati; W Haung Yu; Ellen Sidransky
Journal:  Curr Neurol Neurosci Rep       Date:  2010-05       Impact factor: 5.081

Review 4.  Enzyme replacement therapy in Fabry disease.

Authors:  R O Brady; G J Murray; D F Moore; R Schiffmann
Journal:  J Inherit Metab Dis       Date:  2001       Impact factor: 4.982

5.  The development of the concept of lysosomes. A historical survey, with particular reference to the liver.

Authors:  K Aterman
Journal:  Histochem J       Date:  1979-09

Review 6.  Lysosomal enzyme replacement therapies: Historical development, clinical outcomes, and future perspectives.

Authors:  Melani Solomon; Silvia Muro
Journal:  Adv Drug Deliv Rev       Date:  2017-05-11       Impact factor: 15.470

Review 7.  Enzyme replacement therapy and beyond-in memoriam Roscoe O. Brady, M.D. (1923-2016).

Authors:  Markus Ries
Journal:  J Inherit Metab Dis       Date:  2017-03-17       Impact factor: 4.982

8.  Ultrastructural study of the liver in hepatic prophyria.

Authors:  G Jean; G Lambertenghi; T Ranzi
Journal:  J Clin Pathol       Date:  1968-07       Impact factor: 3.411

9.  Comparative therapeutic effects of velaglucerase alfa and imiglucerase in a Gaucher disease mouse model.

Authors:  You-Hai Xu; Ying Sun; Sonya Barnes; Gregory A Grabowski
Journal:  PLoS One       Date:  2010-05-20       Impact factor: 3.240

10.  Review of the safety and efficacy of imiglucerase treatment of Gaucher disease.

Authors:  Deborah Elstein; Ari Zimran
Journal:  Biologics       Date:  2009-09-15
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.